NOTE: The content below contains the first few paragraphs of the printed article and the titles of the sidebars and boxes, if applicable.
William (Bill) HUMPHRIES Merz Pharma Names CEO of U.S. Holding Company The Merz Pharma Group has appointed William (Bill) Humphries CEO of the U.S. holding company, Merz Inc. Mr. Humphries has overall responsibility for the medical dermatology global business unit and oversees strategic direction and collaboration among three North American companies: Merz Pharmaceuticals, Merz Aesthetics, and Merz Pharma Canada. Mr. Humphries most recently served as the president of Stiefel. He received an MBA from Pepperdine University. Biotechnology POOL Wayne PISANO Former Sanofi Pasteur CEO Joins VaxInnate Wayne Pisano has joined VaxInnate as president and CEO. Mr. Pisano was previously president and CEO of Sanofi Pasteur, the vaccine division of Sanofi. He holds an MBA from the University of Dayton. VaxInnate is a privately held biotechnology company pioneering breakthrough technology for use in developing novel and proprietary vaccines for infectious diseases, including seasonal and pandemic flu, dengue, malaria, and clostridium difficile. Biopharmaceutical POOL Dr. Michelle BARON Kurt GRAVES Intarcia Therapeutics Makes Leadership Changes Intarcia Therapeutics has named Michelle Baron, M.D., VP clinical research and chief medical officer. Dr. Baron is leading clinical development and medical affairs for the biopharmaceutical company, including the global Phase III development of ITCA 650 for the treatment of type 2 diabetes. Dr. Baron joins Intarcia from Sanofi, where she was VP, diabetes U.S. She received an M.D. from Howard University College of Medicine. In other moves, Kurt Graves has been appointed chairman, president, and CEO, concurrent with the company’s plan to open new corporate headquarters in Boston while keeping its early development capabilities and manufacturing site in Hayward, Calif. Mr. Graves has been Intarcia’s executive chairman since August 2010 and its acting CEO since October 2011. He brings to Intarcia more than 20 years of leadership and global experience in pharmaceutical and biotechnology companies. Dr. C. Glenn BEGLEY Former Amgen VP Joins TetraLogic Pharmaceuticals TetraLogic Pharmaceuticals, a biopharmaceutical company developing small molecule Smac mimetic drugs to treat cancer, today announced the appointment of C. Glenn Begley, Ph.D., senior VP of research and development. In addition to leading research and development for TetraLogic, Dr. Begley is overseeing translational studies to support birinapant, the lead Smac mimetic drug candidate in Phase II clinical development. Dr. Begley was previously VP and global head of hematology and oncology research at Amgen. He is board-certified in Australia as a medical oncologist and hematologist and laboratory hematologist and has a Ph.D. in cellular and molecular biology. Mark BOULDING Claudia HIRAWAT PTC Therapeutics Announces Promotions PTC Therapeutics, a biopharmaceutical company focused on the discovery, development, and commercialization of orally administered small-molecule drugs that target post-transcriptional control processes, has announced two promotions among its executive roster. PTC has promoted Mark Boulding to executive VP and chief legal officer, from senior VP and general counsel. Mr. Boulding has been with PTC since 2002. In other moves, Claudia Hirawat has been promoted to president of PTC. Ms. Hirawat joined PTC in 2000 and was most recently senior VP of corporate development. Dr. Keith DIONNE Dr. Mark GOLDSMITH Constellation Announces Top Executive Shift Constellation Pharmaceuticals, a biopharmaceutical company focused on the field of epigenetics, has named Keith Dionne, Ph.D., president and CEO. Dr. Dionne joins Constellation from Third Rock Ventures, where he served as an entrepreneur-in-residence. He received both a Ph.D. in chemical engineering and an M.S. in the program for technology policy from the Massachusetts Institute of Technology. Dr. Dionne succeeds Mark Goldsmith, M.D., Ph.D., who continues as executive chairman of Constellation. Dr. Goldsmith has joined Constellation investor Third Rock Ventures as a venture partner in the firm’s San Francisco office. John SHANNON Durata Taps Former Baxter Executive as Commercial Chief Durata Therapeutics has named John Shannon chief commercial officer. Mr. Shannon’s responsibilities include building the biopharmaceutical company’s commercial team in anticipation of FDA regulatory filing for lead product candidate dalbavancin, now in two pivotal clinical trials for the treatment of patients with acute bacterial skin and skin structure infections. Mr. Shannon joins Durata from Baxter Healthcare, where he most recently served as general manager, global hemophilia and global commercial excellence. Specialty POOL Jennifer BENENSON Dr. Cathryn CLARY Justin DILLON Sean MCKERCHER Lisa PILLA Bill SOUCIE Anthony VENDITTI New Leadership Team for Ipsen Operations in North America Ipsen has completed the appointment of a nine-member U.S. leadership team tasked with advancing business and commercialization activities for its specialty medicines, Somatuline Depot Injection and Dysport for Injection. Jennifer Benenson has joined Ipsen as VP and North American general counsel. Ms. Benenson has 20 years of experience as counsel for the pharmaceutical industry, most recently as VP and general counsel at Daiichi Sankyo. Cathryn Clary, M.D., has been appointed senior VP medical and regulatory affairs, overseeing commercial regulatory affairs, medical affairs activities, safety, and pharmacovigilance. Dr. Clary joins Ipsen from Pfizer, where she was senior VP, U.S. medical and led its U.S. external medical affairs group. Justin Dillon has been named VP and chief compliance officer responsible for ensuring ethics and compliance are embedded in Ipsen business practices and organizational activities. Mr. Dillon was previously deputy compliance officer, North America and Puerto Rico pharmaceutical, vaccines and commercial operations for GlaxoSmithKline. Sean McKercher has been promoted to president and general manager, Ipsen, North America, from senior VP of corporate business development. Mr. McKercher is responsible for overseeing Ipsen regional business strategy and implementation. Lisa Pilla has been named head, neurology franchise, responsible for the overall marketing, sales, and franchise strategy efforts for the company’s lead neurology product, Dysport. Ms. Pilla brings to Ipsen more than 25 years’ experience in pharmaceuticals in the areas of sales, marketing, new product commercialization, and global marketing planning in primary care and specialty. She was most recently VP and business unit head, neurology-psychology division, for Novartis Pharmaceuticals. Bill Soucie has been named VP, market access, responsible for overseeing the company’s payer access strategies, channel operations, reimbursement services, and patient services for Ipsen endocrinology and neurology products. Before joining Ipsen, Mr. Soucie was head of managed markets and payer strategies for Nycomed US and VP, managed markets for Reliant Pharmaceuticals. Anthony Venditti has been appointed head, endocrinology franchise, with responsibility for the overall marketing, sales, and franchise strategy efforts for the company’s lead endocrinology product, Somatuline Depot. Mr. Venditti has more than 30 years of experience in pharmaceutical and specialty product marketing and sales, most recently serving as VP, marketing and sales, for Noven Pharmaceuticals. Dr. Bruce DAUGHERTY Tonix Pharmaceuticals Names Development Director Tonix Pharmaceuticals has appointed Bruce Daugherty, Ph.D., senior director of drug development. Dr. Daugherty brings to Tonix more than 30 years of experience in drug development and scientific research. He most recently served as senior research fellow at Merck. Dr. Daugherty received an MBA from Emory University Goizueta Business School, a Ph.D. in molecular genetics from UMDNJ-Robert Wood Johnson Medical School, and an MS in zoology from Rutgers University. Tonix is a specialty pharmaceutical company developing therapies for challenging disorders of the central nervous system, including fibromyalgia syndrome and post-traumatic stress disorder. Device/Diagnostic POOL Dr. Richard KLOOS Veracyte Appoints Senior Medical Director Veracyte, a molecular diagnostics company focused on the emerging field of molecular cytology, has named Richard Kloos, M.D., senior medical director. Dr. Kloos is responsible for educating the endocrinology community about Veracyte’s first product, the Afirma Thyroid FNA Analysis, as well as leading all thyroid product medical efforts. Dr. Kloos was previously professor in the divisions of endocrinology and metabolism, and nuclear medicine at Ohio State University and was attending physician at The Ohio State University Comprehensive Cancer Center. Discovery POOL Dr. Alain THIBAULT arGEN-X Strengthens Management Team arGEN-X, a preclinical-stage biopharmaceutical company focused on the discovery and development of human monoclonal antibodies from its proprietary Simple Antibody platform, has appointed Alain Thibault, M.D., chief medical officer. Dr. Thibault has 15 years of experience and was previously therapeutic area head of oncology at Regeneron Pharmaceuticals. Association POOL Dr. Judy GARBER Dr. Frank MCCORMICK Dr. Charles SAWYERS Leadership Transition at AACR The American Association for Cancer Research (AACR) has welcomed its new leadership for the 2012-2013 term. Judy Garber, M.D., MPH, is past president 2012-2013, after serving as the AACR president for the 2011-2012 term with distinction. Dr. Garber is director of the Center for Cancer Genetics and Prevention at the Dana-Farber Cancer Institute and a professor of medicine at Harvard Medical School. She is also an associate physician of medicine and attending physician of medical service at Brigham and Women’s Hospital. Dr. Garber has been succeeded by Frank McCormick, Ph.D., D.Sc. (hon.), who has assumed the role of AACR president for 2012-2013. Dr. McCormick is the director of the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center. Additionally, he is the associate dean of the UCSF School of Medicine and a distinguished professor in residence in the department of microbiology and immunology as well as in the department of biochemistry and biophysics. In 1992, Dr. McCormick founded the biotech company Onyx Pharmaceuticals and developed Nexavar, which is used to treat advanced renal cell carcinoma and hepatocellular carcinoma. Charles Sawyers, M.D., has been inaugurated as president-elect, taking the AACR presidency in April 2013. Dr. Sawyers is chair of the Human Oncology and Pathogenesis Program at Memorial Sloan-Kettering Cancer Center and a Howard Hughes Medical Institute investigator. He is also a professor in the cell and developmental biology program and department of medicine at the Joan & Sanford Weill Graduate School of Medical Sciences of Cornell University. Geoff MACKAY Organogenesis CEO Elected MassBio Chairman Geoff MacKay, president and CEO of Organogenesis, has been appointed chairman of the MassBio board of directors. Mr. MacKay will serve a two-year term as board chair. MassBio is a not-for-profit organization that represents and provides services and support for the Massachusetts biotechnology industry. Agency POOL Racheal DODSON Gillian LEONARD Sadie LESSTRANG Nick RAMBKE AbelsonTaylor announces Promotions AbelsonTaylor, an independent advertising agency in the healthcare field, has made several staff changes. Rachael Dodson has been promoted to account supervisor from senior account executive. Ms. Dodson is supervising an anti-infectives account. She has been with AbelsonTaylor since 2006. Gillian Leonard has been promoted to account supervisor from senior account executive. Ms. Leonard continues her work on the consumer side of men’s health, which includes executing television campaigns and large-scale digital efforts. She joined AbelsonTaylor in 2005. Sadie LesStrang has joined AbelsonTaylor as account supervisor, managing products in the area of endocrinology and type 2 diabetes, including the development of four new websites. Ms. LesStrang was previously group account supervisor for Corbett Accel Healthcare Group. She holds an MBA with a concentration in marketing from Roosevelt University in Chicago. Nick Rambke has been promoted to senior account supervisor, spearheading accounts for the treatment of multiple sclerosis, infantile spasms, and kidney disease. Mr. Rambke joined AbelsonTaylor in 2007 as account supervisor. Shannon HARTLEY Rosetta Appoints Healthcare Practice Leader Rosetta, a digital and direct interactive agency operating as an independent brand in the Publicis Groupe of global agencies, has named Managing Partner Shannon Hartley vertical leader for its healthcare practice. Ms. Hartley had served as acting leader since August 2011. Ms. Hartley is responsible for developing and guiding strategies, services, products, and positioning of Rosetta’s healthcare industry vertical, the agency’s largest. She previously led key accounts across the entire healthcare vertical. Jeanine O’KANE Lisa STOCKMAN Chandler Chicco Announces Leadership Shift Global health communications group Chandler Chicco Companies (CCC), part of inVentiv Health, has added executives to leadership roles in its New York offices. Jeanine O’Kane has joined Chandler Chicco Companies as managing director of Biosector 2 (B2) in New York. Ms. O’Kane has more than 20 years of healthcare experience and most recently ran the healthcare group for North America at MSLGroup. Ms. O’Kane succeeds Lisa Stockman, who has been named managing director of CCC New York. Ms. Stockman, who has been with Chandler Chicco Companies since its inception, has directed numerous award-winning campaigns. David ZARITSKY Roska Healthcare Names New President Roska Healthcare Advertising has named David Zaritsky president, succeeding Jay Bolling, who remains CEO of the agency. Mr. Zaritsky’s responsibilities include strategic planning and development, business development staff management, and managing long-term client relationships. He was previously managing director of Healthcare Regional Marketing. Consulting POOL Paul SONNIER Popper Appoints Digital Health Strategy Lead Popper and Co. has extended its reach into digital health and expanded its geographic scope with the appointment of Paul Sonnier as head of digital health strategy. Mr. Sonnier began working with Popper in the second half of 2011 as a strategic advisor. Popper and Co. is an mergers and acquisition advisory and specialty consulting firm dedicated to help clients across the life-sciences spectrum address complex business challenges. Jerry WOLF Compliance Implementation Services Strengthens Government Pricing Capabilities Compliance Implementation Services (CIS), a life-sciences consulting firm, has named Jerry Wolf senior director, government pricing compliance consulting. Mr. Wolf is charged with overseeing the company’s consulting services and support for many of its clients’ government programs participation. Mr. Wolf was previously a director in a specialized consulting firm’s healthcare disputes, compliance, and investigations practice. In addition to being a registered pharmacist, Mr. Wolf’s background includes more than 25 years in the pharmaceutical and managed healthcare industries. Media POOL Tim DAVENPORT Sermo appoints New CEO Sermo, an online community exclusive to physicians, has appointed Tim Davenport CEO. Mr. Davenport has an extensive track record as an Internet, software, and healthcare executive, and was formerly president of Revolution Health, a digital health company. He received an MBA from Harvard Business School. Service POOL Dr. Valerio AIMALE Dr. William HOWARD Delphina PERKINS Qforma Appoints Three Executives Qforma, a healthcare data analytics and predictive modeling company, has added three executives. Valerio Aimale, M.D., has been named chief, advanced projects, leading product research and development initiatives. Dr. Aimale has spent 15 years in molecular biology research, internal medicine, and complexity and computer science and has extensive expertise in the area of familial hypercholesterolemia. He received an M.D. from the University of Genoa in Italy. William Howard, Ph.D., has been appointed senior VP, new product development. Dr. Howard previously led Qforma’s client services division. He received a Ph.D. as a Hertz Foundation Fellow in applied nuclear and medical physics from the Massachusetts Institute of Technology. Delphina Perkins has joined Qforma as director, client services. Ms. Perkins received an MBA with a concentration in marketing from the University of Texas at Austin’s McCombs School of Business. Richard DERISIO Covidien Names Regulatory Affairs VP Covidien, a global provider of healthcare products, has appointed Richard DeRisio VP, global quality assurance and regulatory affairs. Mr. DeRisio’s duties include establishing and implementing processes enabling continuous improvement and proficiency; selecting and managing supporting technology platforms; and assisting in designing and deploying strategies to facilitate global alignment of Covidien’s quality assurance and regulatory affairs policies, procedures, and best practices. Mr. DeRisio was most recently divisional vice president, regulatory affairs, for Abbott Medical Optics. He received a master’s degree in food science and technology from Cornell University. Stuart NEEDLEMAN Aptuit Promotes President Stuart Needleman has been named president and chief operating officer of global pharmaceutical services company Aptuit. Following the recent sale of the company’s clinical trials supply business, Mr. Needleman has been promoted from his previous position of president, scientific operations. He received an MBA from Rensselaer Polytechnic Institute. Pharmaceutical POOL Michael HOLSTON Merck Appoints Compliance Chief Merck has named Michael Holston chief ethics and compliance officer, succeeding Richard Bowles, who has decided to retire from the company after more than 35 years with Merck and the former Schering-Plough. Mr. Holston most recently served as executive VP and general counsel for Hewlett-Packard. He received a J.D. from Villanova University School of Law. Biotechnology POOL Jacob BENARIE Dr. Sarah FERBER Orgenesis Names Executive Leadership Orgenesis, a development-stage company with a novel therapeutic technology dedicated to convert a patient’s own liver cells into functional insulin-producing cells as a treatment for diabetes, has appointed Jacob BenArie CEO. Mr. BenArie served for the past five years as the CEO of Beta-Stim. He received an MBA from the Technion-Israel Institute of Technology. Sarah Ferber, Ph.D., has joined Orgenesis as chief science officer. Dr. Ferber studied biochemistry at Technion and completed a postdoctoral fellowship at the Joslin Diabetes Center at Harvard Medical School. Hans BISHOP Genesis Biopharma Appoints Executive Chairman Genesis Biopharma, a biotechnology company developing targeted cancer immunotherapies, has named Hans Bishop executive chairman. Mr. Bishop was previously chief operating officer of Dendreon. Dr. Patrick GRIFFIN ImmusanT Appoints Medical Chief Patrick Griffin, M.D., has joined ImmusanT as chief medical officer and senior VP of development. ImmusanT is a privately held biotechnology company focused on restoring tolerance to gluten in celiac disease by harnessing new discoveries in immunology. Dr. Griffin, a board-certified physician in both internal medicine and gastroenterology, was most recently head of external innovation for Sanofi’s immunoinflammation therapeutic strategy unit. He received a medical degree from Columbia University. Dr. Duane NASH Vital Therapies Selects Medical Director Vital Therapies, a development-stage biotechnology company focused on allogeneic cellular therapy for acute liver failure, has appointed Duane Nash, M.D., chief business officer and medical director. Dr. Nash joins Vital Therapies from Wedbush PacGrow Life Sciences, where he was senior VP in equity research. He received an M.D. from Dartmouth Medical School, a J.D. from the University of California, Berkeley, and an MBA from the University of Oxford. Biopharmaceutical POOL Dr. George FARMER Dr. Dvorit SAMID Synta Pharmaceuticals Appoints VPs Synta Pharmaceuticals has named George Farmer, Ph.D., VP of corporate development, leading the biopharmaceutical company’s communications, competitive intelligence, and strategy functions. Dr. Farmer was most recently a senior analyst with Canaccord Genuity. He received a Ph.D. in biological sciences from Columbia University. Dvorit Samid, Ph.D., has joined Synta as VP of medical affairs. Dr. Samid has extensive experience in oncology drug development for companies such as Roche and ImClone and has also held positions in academia and government. She received a Ph.D. in cell biology from the Catholic University of America. Antoun NABHAN Tobira Selects Business Development VP Tobira Therapeutics has appointed Antoun Nabhan VP, business development, with responsibility for strategic transactions and partnering activities, as well as certain operating activities. Mr. Nabhan joins Tobira from Onyx Pharmaceuticals. Tobira is a biopharmaceutical company focused on the development and commercialization of innovative therapies that address important and unmet medical needs in infectious diseases, with a current focus on HIV/AIDS. Rohan PALEKAR Avanir Appoints Commercial Chief Avanir Pharmaceuticals, a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need, has named Rohan Palekar senior VP and chief commercial officer. Mr. Palekar joins Avanir from Medivation, where he was chief commercial officer. He received an MBA from the Amos Tuck School of Business at Dartmouth College. Specialty POOL Paul MEDEIROS Mundipharma Expands Executive Roster Mundipharma International has appointed Paul Medeiros to head its corporate and business development operations. Mr. Medeiros has almost two decades of experience in biopharmaceutical business development and commercialization, most recently as senior VP and chief business officer for AVI BioPharma. He earned an MBA from Columbia Business School. The Mundipharma/Napp/Norpharma independent associated companies are privately owned companies and joint ventures dedicated to bringing to patients worldwide the benefits of novel treatment options in fields such as severe pain, hemato-oncology, and respiratory disease. Dr. Thomas OTTOBONI A.P. Pharma Appoints Development VP A.P. Pharma, a specialty pharmaceutical company developing products using its proprietary Biochronomer polymer-based drug delivery technology, has named Thomas Ottoboni, Ph.D., VP of pharmaceutical development. Dr. Ottoboni was most recently VP of research and development at Talima Therapeutics. Dr. Ottoboni is an inventor on more than 19 U.S. patents in organic and macromolecular chemistry. He received a Ph.D. in organic chemistry from the University of California, Berkeley. Dr. Noah ROSENBERG Esperion Names Medical Chief Esperion Therapeutics, a company focused on discovering and developing novel therapies for the treatment of cardiovascular and metabolic diseases, has appointed Noah Rosenberg, M.D., chief medical officer. Dr. Rosenberg’s duties include leading the Esperion clinical advisory board and developing and managing the company’s clinical programs. Over the past decade, Dr. Rosenberg has held senior posts in the pharmaceutical industry, including leadership roles in medical affairs, clinical development, and administration in the United States and globally and was most recently with Forest Research Institute. Dr. Rosenberg earned an M.D. from Drexel University. Genomics POOL Adam ROSENBERG Dr. Jay THERRIEN Knome Names VPs Knome, a human genome interpretation company, continues to strengthen its executive management team with the addition of two VPs. Adam Rosenberg has joined Knome as senior VP and head of corporate development. Mr. Rosenberg is responsible for all transactional aspects of the company, in addition to developing Knome’s intellectual property strategy and playing a leadership role in establishing Knome’s partnerships in the pharmaceutical/biotech industry. For the last three years, Mr. Rosenberg has advised emerging companies as a director and consultant and co-founded Clean Membranes. He received a J.D. from University of Virginia School of Law. Jay Therrien, Ph.D., has been appointed senior VP and head of global sales. Most recently, Dr. Therrien was VP, commercial operations, sequencing, at Life Technologies. He has a Ph.D. from the University of Kansas. Agency POOL Zhanna AGRAN Liz BARNES Victor BROVIN Jocelyn FARHANGIAN Daniel HAMMER John KNUTILA Shelley REICH Daniel SONTUPE The CementBloc, a multichannel health and wellness creative agency, has made a number of new additions and promotions to its staff. Zhanna Agran has joined The CementBloc’s editorial team as senior medical editor. Ms. Agran was previously with Cline Davis & Mann. Liz Barnes has been named multichannel project manager. Ms. Barnes joins The CementBloc from Grey Healthcare Group. Victor Brovin has been appointed associate director, multichannel project management. Mr. Brovin was most recently with Cline Davis & Mann. Jocelyn Farhangian has joined The CementBloc as account director on the Cimzia business. Ms. Farhangian was previously with Ignite Health. Joining The CementBloc’s market access team as group account director is Daniel Hammer, who was previously with Cline Davis & Mann’s Entrée Health division. John Knutila has been appointed group copy director. Mr. Knutila was most recently with HealthEd. Shelley Reich has been named VP, market access. Ms. Reich joins The CementBloc after previously consulting with Pharmacision. Daniel Sontupe, senior VP, managed markets, has taken on the market access and reimbursement leadership role at The CementBloc. Mr. Sontupe is responsible for overseeing all of the agency’s payer strategy work. He joined The CementBloc in November 2010. Dr. Michael BARNETT Jim MORAN Lorna WEIR Vox Medica Names Leadership Team Michael Barnett, M.D., D.Phil., and Jim Moran have joined healthcare communications company Vox Medica as executive VPs and equity partners. Both Dr. Barnett and Mr. Moran spent several years at Dorland Global prior to establishing their own strategic consulting practice, Transit of Venus, which is becoming an independent subsidiary of Vox Medica focused on strategic consulting and nonpromotional public health programs. In other moves, Vox Medica President Lorna Weir has been made an equity partner. Steve HAMBURG Industry Veteran Joins LLNS as Creative Chief Professional healthcare marketing agency LLNS, an Omnicom company, has appointed Steve Hamburg chief creative officer. Mr. Hamburg is responsible for leading creative both for LLNS and the VUE Group network. Mr. Hamburg joins LLNS from Rosetta, where he was most recently chief creative partner. CONSULTING POOL Detlef NEHRDICH Waife & Associates Adds Senior Associate Waife & Associates (W&A), change management consultants in biopharmaceutical clinical research, has appointed Detlef Nehrdich a senior associate based near Frankfurt, Germany. Mr. Nehrdich comes to W&A from Abbott Laboratories, where he was most recently site head, statistics and data management, in Ludwigshafen, Germany and global director of EDC operations. He earned a M.Sc. in statistics from the University of Dortmund in Germany. CRO POOL William BOTHA Former Genzyme Manager Joins Avrio Biopharmaceuticals Avrio Biopharmaceuticals has named William Botha president. Mr. Botha has more than two decades of experience in manufacturing and the pharmaceutical, biotech, and medical device industries. He was most recently senior director of operational excellence at Genzyme. Avrio, an affiliate of Irvine Pharmaceutical Services, is a contract development and manufacturing organization providing support to the pharmaceutical, biopharmaceutical, and medical device industries. Lisa COZZA New Business Development VP at Laureate Laureate Biopharmaceutical Services, a full-service biopharmaceutical contract development and manufacturing organization, has named Lisa Cozza VP, business development. Ms. Cozza most recently served as executive director of manufacturing alliances at Human Genome Sciences. Ms. Cozza received an MBA from Northeastern University. Dr. Richard LELACHEUR Agilux Bolsters Bioanalytical Expertise Agilux Laboratories, a provider of pharmaceutical and biotech drug discovery and development research services, has appointed Richard LeLacheur, Ph.D., senior director, bioanalytical operations. Dr. LeLacheur is working with the discovery and GLP bioanalysis groups to drive scientific and operational processes and improvements. Dr. LeLacheur has held operational roles of increasing responsibility in a number of contract research organizations. Dr. Evan ROSENFELD Theorem Names Scientific Affairs VP Theorem Clinical Research, a full-service CRO that provides core clinical research and development services, has appointed Evan Rosenfeld, M.D., VP of medical and scientific affairs, medical device and diagnostics. Dr. Rosenfeld previously served as the medical director and senior consultant for regulatory and clinical affairs at Emergo Group. At the same time, he founded MDJD Consulting and worked as an independent consultant providing medical, clinical and regulatory analysis, insights, and strategic recommendations. Dr. Rosenfeld graduated cum laude from the University of Pennsylvania Law School and obtained a medical degree from the Virginia Commonwealth University School of Medicine. Media POOL Dr. Stefano DEL PRATO Dr. Vivian FONSECA Dr. Steven KAHN Elsevier Names Senior Editorial Team for Diabetes Journal Elsevier has appointed a new senior editorial team for its Journal of Diabetes and its Complications. Stefano Del Prato, M.D., has been named an associate editor. Dr. Del Prato is professor of endocrinology and metabolism at the School of Medicine, University of Pisa, and chief of the section of diabetes at the University of Pisa in Italy. He also serves as clinical associate professor of medicine at the University of Texas Health Science Center at San Antonio. Dr. Del Prato obtained an M.D. cum laude from the University of Padova in Italy. Vivian Fonseca, M.D., has been appointed editor-in-chief. Dr. Fonseca is professor of medicine, Tullis-Tulane Alumni Chair in Diabetes, and chief of the section of endocrinology at Tulane University Medical Center. He is also president for science and medicine at the American Diabetes Association. Steven Kahn, MBChB, has joined the journal as an associate editor. Dr. Kahn is professor of medicine, division of metabolism, endocrinology and nutrition, University of Washington, VA Puget Sound Health Care System. He received an MBChB from the University of Cape Town in South Africa. Service POOL Olivier DUMON Jay KATZEN Elsevier Announces Government Research Markets Change Elsevier, a provider of scientific, technical, and medical information products and services, has named Olivier Dumon managing director of its academic and government research markets group. Mr. Dumon brings more than 15 years of international experience to Elsevier, including stints at eBay and AT&T Interactive. He has an MBA from Harvard Business School. Mr. Dumon succeeds Jay Katzen, who is now managing the clinical decision support department in Elsevier’s health sciences division. Colleen DUREAU-INZERILLO New Global Business Development Head at Novella Clinical Resourcing Colleen Dureau-Inzerillo has joined Novella Clinical Resourcing, a division of Novella Clinical, as global head of business development. Ms. Dureau-Inzerillo is responsible for leading sales strategy and implementation through Novella Clinical Resourcing’s field sales group to deliver new authorizations in staff placements, functional service provider (FSP) models, and other clinical staffing solutions. She previously served as VP of business development for an unnamed U.S.-based clinical staffing and outsourcing company. Brian HEALY Nigel THOMPSON Albright Adds Former Merck Executives to Advisory Team Albright Stonebridge Group (ASG), a global strategy firm, has appointed two senior directors specifically focused on advising the firm’s biopharmaceutical clients on economic and regulatory issues around the world. As senior director, Brian Healy is helping to build ASG’s expertise in global healthcare and biopharmaceutical market issues. Mr. Healy spent three decades at Merck, most recently as VP, policy and communications. Nigel Thompson has joined ASG as senior director, advising the firm’s biopharmaceutical clients on worldwide regulatory issues. Mr. Thompson most recently was executive director, economic and development strategy, and before joining ASG served as president of Parks Pharma Consulting. Technology POOL Prajeep Kumar THOTTUPURATH QPharma Promotes Information Chief QPharma has promoted Prajeep Kumar Thottupurath to chief information officer (CIO), with responsibility for charting the strategic direction of life-sciences consulting company’s technology products and infrastructure. Mr. Thottupurath was director of information technology, and will continue to oversee day-to-day operations in the information technology division.